PathoGene, Inc. is a private, seed-stage precision MedTech startup headquartered in Los Angeles, with R&D operations located in Monrovia, California. We are developing a sample-to-answer in vitro diagnostic medical device that detects and identifies all known microscopic human pathogens along with their antimicrobial resistance profiles on a single 6-hour test panel. To do this, we leverage robotic automation, third-generation DNA and RNA sequencing, and cloud computing technologies to report a molecular diagnosis to care providers and disease surveillance systems in real-time. Our goal is to deliver the necessary diagnostic tools for doctors and medical staff to make optimal treatment decisions that can ultimately improve public health as a whole, and we believe that our sample-to-answer technology can become the global standard of care for diagnosing infectious diseases.
Looking for a particular PathoGene, Inc. employee's phone or email?
The PathoGene, Inc. annual revenue was $7.8 million in 2026.
Joseph Mickel is the CEO of PathoGene, Inc..
2 people are employed at PathoGene, Inc..
PathoGene, Inc. is based in Monrovia, California.
The NAICS codes for PathoGene, Inc. are [621, 561, 56, 62].
The SIC codes for PathoGene, Inc. are [80, 8071, 738, 807, 73].